Chemocentryx

ChemoCentryxis a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer. ChemoCentryx focuses on the discovery, development, and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors. The company's small molecule product candidates are designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen

Amgen (AMGN) is buying ChemoCentryx (CCXI) for $4 billion in cash. These are the details.

Why Amgen (AMGN) Is Buying ChemoCentryx (CCXI) For $4 Billion In Cash

The rare-disease specialist is being bought out at a sizable premium.

Why ChemoCentryx Stock Is On Fire Today

Amgen agreed to buy ChemoCentryx for $3.7 billion on Thursday, leading CCXI stock to rocket by a triple-digit percentage. The post Amgen Plans $3.7 Billion ChemoCentryx Buyout, Tapping Into A New Market appeared first on Investor's Business Daily.

Amgen Plans $3.7 Billion ChemoCentryx Buyout, Tapping Into A New Market

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of ChemoCentryx, Inc. (NASDAQ: CCXI) to Amgen Inc. for $52.00 per share in cash is fair to ChemoCentryx shareholders. Halper Sadeh encourages ChemoCentryx shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether ChemoCentr

CCXI Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of ChemoCentryx, Inc. Is Fair to Shareholders

With the acquisition, the biotech company adds a newly approved drug for an autoimmune disorder.

Amgen Acquires Drugmaker ChemoCentryx for $3.7 Billion

Amgen Inc. AMGN, +1.32% said Thursday it plans to buy ChemoCentryx Inc. CCXI, +3.61% for $3.7 billion in cash. The deal will give Amgen access to Tavneos, a treatment for ANCA-associated vasculitis that received approval from the Food and Drug Administration in October.

Amgen to gain rare-disease drug in $3.7 billion acquisition of ChemoCentryx

Amgen Inc said on Thursday it would buy ChemoCentryx Inc for $3.7 billion as the U.S. drugmaker seeks to bolster its portfolio with a newly approved potential blockbuster anti-inflammation treatment.

Amgen adds potential blockbuster drug with $3.7 bln ChemoCentryx deal

Acquisition Includes TAVNEOS® (avacopan), a First-in-Class Medicine for Patients With Serious Autoimmune Disease  Tavneos Adds to Amgen's Decades-Long Leadership in Inflammation and Nephrology THOUSAND OAKS, Calif. and SAN CARLOS, Calif.

AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH

SAN CARLOS, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's second quarter 2022 financial results will be released after market close on Tuesday, August 9, 2022. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on August 9, 2022 to discuss these results and to answer questions.

ChemoCentryx to Hold Second Quarter 2022 Financial Results Conference Call on Tuesday, August 9, 2022

ChemoCentryx (CCXI) has only one product approved for sale in its portfolio, Tavneos. Nevertheless, it is progressing well with the clinical development of its pipeline candidates.

ChemoCentryx's (CCXI) Tavneos Aids Growth, Overdependence a Woe

-- Ms. Herron brings more than 25 years of therapeutics commercial experience and brand management to ChemoCentryx Board -- -- Ms. Herron brings more than 25 years of therapeutics commercial experience and brand management to ChemoCentryx Board --

ChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent Director

-- Consistent with approved antibody inhibitors of PD-L1, CCX559 demonstrates immunomodulatory activity in first cycle of treatment -- -- Safety and tolerability allow for continued dose escalation with no dose limiting toxicities to date --

ChemoCentryx Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

SAN CARLOS, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced upcoming abstract presentations at three key medical conferences taking place in June, which highlight TAVNEOS® (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, and its role in ANCA-associated vasculitis and potential application in C3 glomerulopathy, as well as the immuno-oncology potential of CCX559, an orally administered small molecule PD-L1 inhibitor.

ChemoCentryx Announces Abstracts at June Rheumatology, Oncology and Nephrology Conferences

-- David E. Wheadon, M.D., Elected to the Board as an Independent Director -- -- Henry A. McKinnell, Jr., to Retire from Board --

ChemoCentryx Announces Changes to its Board of Directors

-- Supports plans to advance TAVNEOS ® (avacopan) into Phase III development for the treatment of patients with most severe form of hidradenitis suppurativa, Hurley Stage III -- SAN CARLOS, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that a poster will be presented at the Society for Investigative Dermatology (SID) 2022 Annual Meeting, to be held May 18-21, 2022 in Portland, Oregon, that highlights unique immunological profiles of the subdermal tunnels in hidradenitis suppurativa, and how these profiles are differentiated with the stage of disease severity. The findings support the Company's plans to advance TAVNEOS® (avacopan) into Phase III development for the treatment of patients with Hurley Stage III (severe) hidradenitis suppurativa.

ChemoCentryx Announces Presentation at the Society for Investigative Dermatology Meeting Highlighting the Role of Tunnels in Driving Ongoing Disease in Hidradenitis Suppurativa

SAN CARLOS, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference on Tuesday, May 24, 2022 at 12:30 p.m. ET. The conference will be held at the Fontainebleau Miami Beach Hotel in Miami, FL.

ChemoCentryx to Present at the H.C. Wainwright Global Investment Conference

SAN CARLOS, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced upcoming presentations at three key medical conferences that will highlight findings from the pivotal Phase III ADVOCATE trial that supported the approval of TAVNEOS® (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, and research into the burden of glucocorticoid use in ANCA-associated vasculitis.

ChemoCentryx Announces Upcoming Conference Abstracts Focused on TAVNEOS® (avacopan) and the Burden of Systemic Glucocorticoid Use in ANCA-Associated Vasculitis

In the wake of its first quarter earnings report, ChemoCentryx ran as much as 25% on Friday as the broader market fell. The move could mark an important inflection point for a stock that had been in a sharp downturn since October.

ChemoCentryx: A Biotech Stock Well Worth the Risk

ChemoCentryx (CCXI) posts a wider-than-anticipated Q1 loss and a revenue lag. However, product sales of CCXI's recently approved drug Tavneos grow five-fold from the previous quarter's levels.

ChemoCentryx (CCXI) Q1 Earnings and Sales Miss Estimates

ChemoCentryx Inc (NASDAQ: CCXI) shares are trading higher by 21.45% at $19.00 after the company reported first-quarter results. ChemoCentryx reported quarterly losses of 55 cents per share which missed the analyst consensus estimate of a loss of 30 cents.

Why ChemoCentryx Shares Are Popping Off

ChemoCentryx, Inc. (NASDAQ:CCXI ) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Dr. Thomas Schall – Chairman, President and Chief Executive Officer Tausif Butt – Executive Vice President, Chief Operating Officer Susan Kanaya – Executive Vice President, Chief Financial and Administrative Officer Bill Slattery, Jr. – Vice President of Investor Relations & Corporate Communications Conference Call Participants Joseph P. Schwartz – SVB Leerink Ryan Deschner – Raymond James Yanan Zhu – Wells Fargo Securities Dae Gon Ha – Stifel Nicolaus Anupam Rama – J.P.

ChemoCentryx, Inc. (CCXI) CEO Dr. Thomas Schall on Q1 2022 Results - Earnings Call Transcript

ChemoCentryx (CCXI) delivered earnings and revenue surprises of -83.33% and 78.77%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ChemoCentryx (CCXI) Reports Q1 Loss, Misses Revenue Estimates

ChemoCentryx (CCXI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will ChemoCentryx (CCXI) Report Negative Q1 Earnings? What You Should Know

SAN CARLOS, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's first quarter 2022 financial results will be released after market close on Thursday, May 5, 2022. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on May 5, 2022 to discuss these results and to answer questions.

ChemoCentryx to Hold First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022

-- Human pharmacokinetics (PK) reveal CCX559 exposure tracking with projections, with good oral availability and expected half-life -- -- Pharmacodynamic (PD) results show CCX559 exhibits immune stimulatory properties in cancer patients --

ChemoCentryx Reports Pharmacokinetic and Pharmacodynamic Results from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at American Association for Cancer Research (AACR) Annual Meeting 2022

News for Chemocentryx Stock (CCXI)